前列腺癌靶向基因治疗实验研究的最新进展  

The latest advances of experimental research on targeted gene therapy for prostate cancer

作　　者：潘东亮[1,2] 那彦群[1,2] 

机构地区：[1]北京大学首钢医院泌尿外科 [2]北京大学吴阶平泌尿外科医学中心,北京100144

出　　处：《中国癌症杂志》2012年第12期942-946,共5页China Oncology

基　　金：中国科学院环境化学与生态毒理学国家重点实验室开放基金(No:KF2011-12)

摘　　要：由于去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC)缺乏有效的治疗方法催生了探索新治疗模式的需求,其中靶向基因治疗是治疗前列腺癌较理想的模式。但因缺乏令人满意的基因载体以及旁观者效应的降低而影响了其临床应用,为此世界各地的科学家进一步致力于靶向基因、载体、应用方法和治疗方案的实验研究,本文就CRPC靶向基因治疗的最新研究成果作一综述。The absence of effective therapies for castration-resistant prostate cancer （CRPC） establishes the need to develop novel therapeutic modality, such as targeted gene therapy, which is ideal for the treatment of CRPC. But its application has been limited due to lack of favorable gene vector and the reduction of ＂by-stander effect＂. Consequently, scientists all over the world focus their main experimental research on the following 4 aspects： targeted gene, vector, transfer means and comprehensive therapy. In this paper, we reviewed the latest advances on targeted gene therapy for prostate cancer.

关 键 词：前列腺癌 靶向基因 治疗 实验研究 

分 类 号：R737.25[医药卫生—肿瘤]